Big Buttons

• FDA to continue enforcement discretion on compounded tirzepatide

  Important answers to your questions about the current state of FDA’s enforcement when it comes to compounded tirzepatide injections.  read more →

• Another reason to attend the Owner Summit

  We’ve got another awesome keynote at the 2025 Owner Summit: “16 Ways to Improve Employee Engagement” with Allison Linney. read more →

• A different approach to regulation

  The Texas State Board of Pharmacy is taking a different approach to USP chapter implementation. read more →

• OFA v. Califf: The latest

  If you missed our email earlier this week, here’s an update for you on the Outsourcing Facilities Association/Farmakeio lawsuit against FDA. read more →

• Reason #2 to come to the APC Owner Summit

  Our second keynote will help you plan your business strategy. read more →

• ADA parrots drugmakers on GLP-1 copies

  We call out the American Diabetes Association's 'alternative facts' about compounded GLP-1s read more →

• A good time to sharpen your skills

  It's time to get up to snuff when it comes to compounding best practices (and we can help). read more →

• Lilly intervenes in OFA lawsuit against FDA

  Lilly says the FDA isn’t allowed to decide when compounders can compound FDA-approved drugs. read more →

More News

The Texas State Board of Pharmacy is taking a different approach to USP chapter implementation. While the board embraces much of what USP 797 recommends, it also goes its own way on certain issues. APC submitted comments on the proposed rules this week.